An abridged complaints procedure, the option to use QR codes and the need for companies to explain why they are providing support for doctors to attend events are among the changes proposed for the Association of the British Pharmaceutical Industry’s updated code of practice.
The Association of the British Pharmaceutical Industry wants its member companies to start conducting an “educational needs assessment” to explain why they are providing support for health professionals or other relevant decision makers to attend events and meetings.
Companies should also have written agreements in place setting out what has been with agreed in relation to the support...
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
AbbVie’s migraine ad overstates the drug’s benefit, a problem that is amplified by using a celebrity, the agency says.
The lung cancer drug Krazati from Bristol Myers Squibb’s Mirati Therapeutics drew an FDA ad/promo untitled letter, highlighting the agency's trend of pursuing false or misleading efficacy claims, particularly when data comes from outside approved labeling.
The UK and EU pharma industry associations have defended their respective codes of practice despite alarming study results. Meanwhile, a consultation on proposals to revise the UK code received over 3,500 comments.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
